Allosteric modulators for
human health
About us
Addex Corporate Presentation
Overview
Our people
Executive Officers
Non-Executive Directors
Contact
Privacy Policy
Careers
Pipeline
Clinical and Pre-Clinical Pipeline
Research And Development
Technology
Allosteric modulation
Publications
Partners & collaboration
Investors
Addex corporate Presentation
Stock Data
Press releases
Ad hoc announcements (Art. 53 L.R)
Events
Financial Reports
Analyst Reports
General Meetings
SEC / SIX Filings
Guide to US ADSS for Six Shareholders
Register for email news
Corporate Governance
Contact
Media
Press releases
Contact
Press releases
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
Please select year
06.05
2012
Addex Partner to Initiate Phase 2 Clinical Trial of ADX71149 for the Treatment of Major Depressive Disorder with Anxiety Symptoms
05.09
2012
Addex Shareholders Approve All Board Proposals at Annual General Meeting
04.16
2012
Addex Reports Positive Preclinical Data for GABA-BR PAM Oral Small Molecule in Overactive Bladder
04.13
2012
Addex Takes Steps to Rightsize Operations and Position the Company for Future Success
03.21
2012
Addex changes name to Addex Therapeutics
03.21
2012
Addex Reports Positive Top Line Phase IIa Data for Dipraglurant in Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID)
02.23
2012
Addex Pharmaceuticals Reports 2011 Financial Results
02.21
2012
Addex Pharmaceuticals 2011 Financial Results this Thursday
02.10
2012
Addex to present at the BIO CEO & Investor Conference
11.28
2011
Addex Scientists Discover Glucagon-like-peptide-1 (GLP-1) Induced Interaction Between GLP-1 and Gastric Inhibitory Peptide (GIP) Receptors the addex allosteric modulator platform enabled breakthrough discovery, advancing the understanding of glp-1 mediated gpcr signaling
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
Next
Back